Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Cancer survivorship and work loss – what are the risks and determinants?

Cancer survivorship and work loss – what are the risks and determinants? Acta Oncologica, 2014; 53: 721–723 EDITORIAL Cancer survivorship and work loss – what are the risks and determinants? KARIN E. SMEDBY Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden and Center for Hematology, Karolinska University Hospital, Stockholm, Sweden Cancer survivorship is a fi eld of growing clinical and phoma) [8] indicated a considerable long-standing scientifi c interest. Two circumstances logically con- work impairment among survivors. However, these tribute to this development; a general increase in older studies showed disparate results, and relied on cancer incidence, and an improved cancer survival cross-sectional designs and self-reported data with- [1,2], both leading to a higher prevalence of cancer out comparison to the general population, limiting survivors. In the European Union in 2012, the num- the generalizability of the fi ndings (reviewed in [8]). ber of individuals diagnosed with cancer within the Also, given the considerable modifi cations in treat- past fi ve years totaled 7.2 million [3]. In this con- ment schedules for Hodgkin lymphoma patients [9], text, it has been stressed that the challenge in over- results are diffi cult to apply today. In the 21st cen- coming cancer is not only to fi nd effi cient therapies http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Oncologica Taylor & Francis

Cancer survivorship and work loss – what are the risks and determinants?

Acta Oncologica , Volume 53 (6): 3 – Jun 1, 2014

Cancer survivorship and work loss – what are the risks and determinants?

Acta Oncologica , Volume 53 (6): 3 – Jun 1, 2014

Abstract

Acta Oncologica, 2014; 53: 721–723 EDITORIAL Cancer survivorship and work loss – what are the risks and determinants? KARIN E. SMEDBY Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden and Center for Hematology, Karolinska University Hospital, Stockholm, Sweden Cancer survivorship is a fi eld of growing clinical and phoma) [8] indicated a considerable long-standing scientifi c interest. Two circumstances logically con- work impairment among survivors. However, these tribute to this development; a general increase in older studies showed disparate results, and relied on cancer incidence, and an improved cancer survival cross-sectional designs and self-reported data with- [1,2], both leading to a higher prevalence of cancer out comparison to the general population, limiting survivors. In the European Union in 2012, the num- the generalizability of the fi ndings (reviewed in [8]). ber of individuals diagnosed with cancer within the Also, given the considerable modifi cations in treat- past fi ve years totaled 7.2 million [3]. In this con- ment schedules for Hodgkin lymphoma patients [9], text, it has been stressed that the challenge in over- results are diffi cult to apply today. In the 21st cen- coming cancer is not only to fi nd effi cient therapies

Loading next page...
 
/lp/taylor-francis/cancer-survivorship-and-work-loss-what-are-the-risks-and-determinants-20pofMr0dC

References (29)

Publisher
Taylor & Francis
Copyright
© 2014 Informa Healthcare
ISSN
1651-226X
eISSN
0284-186X
DOI
10.3109/0284186X.2014.913103
Publisher site
See Article on Publisher Site

Abstract

Acta Oncologica, 2014; 53: 721–723 EDITORIAL Cancer survivorship and work loss – what are the risks and determinants? KARIN E. SMEDBY Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden and Center for Hematology, Karolinska University Hospital, Stockholm, Sweden Cancer survivorship is a fi eld of growing clinical and phoma) [8] indicated a considerable long-standing scientifi c interest. Two circumstances logically con- work impairment among survivors. However, these tribute to this development; a general increase in older studies showed disparate results, and relied on cancer incidence, and an improved cancer survival cross-sectional designs and self-reported data with- [1,2], both leading to a higher prevalence of cancer out comparison to the general population, limiting survivors. In the European Union in 2012, the num- the generalizability of the fi ndings (reviewed in [8]). ber of individuals diagnosed with cancer within the Also, given the considerable modifi cations in treat- past fi ve years totaled 7.2 million [3]. In this con- ment schedules for Hodgkin lymphoma patients [9], text, it has been stressed that the challenge in over- results are diffi cult to apply today. In the 21st cen- coming cancer is not only to fi nd effi cient therapies

Journal

Acta OncologicaTaylor & Francis

Published: Jun 1, 2014

There are no references for this article.